Eupraxia Pharmaceuticals (EPRX) Competitors $5.26 -0.13 (-2.41%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.26 +0.00 (+0.10%) As of 08/8/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. NAGE, GHRS, VIR, ANAB, AMLX, DAWN, STOK, KALV, MNMD, and ATAIShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Niagen Bioscience (NAGE), GH Research (GHRS), Vir Biotechnology (VIR), AnaptysBio (ANAB), Amylyx Pharmaceuticals (AMLX), Day One Biopharmaceuticals (DAWN), Stoke Therapeutics (STOK), KalVista Pharmaceuticals (KALV), Mind Medicine (MindMed) (MNMD), and atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Niagen Bioscience GH Research Vir Biotechnology AnaptysBio Amylyx Pharmaceuticals Day One Biopharmaceuticals Stoke Therapeutics KalVista Pharmaceuticals Mind Medicine (MindMed) atai Life Sciences Niagen Bioscience (NASDAQ:NAGE) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation. Is NAGE or EPRX more profitable? Niagen Bioscience has a net margin of 15.24% compared to Eupraxia Pharmaceuticals' net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Niagen Bioscience15.24% 23.12% 15.53% Eupraxia Pharmaceuticals N/A -367.73%-112.23% Do analysts recommend NAGE or EPRX? Niagen Bioscience presently has a consensus price target of $13.22, indicating a potential upside of 35.87%. Eupraxia Pharmaceuticals has a consensus price target of $11.00, indicating a potential upside of 109.13%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Which has more volatility and risk, NAGE or EPRX? Niagen Bioscience has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Does the media prefer NAGE or EPRX? In the previous week, Niagen Bioscience had 15 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 16 mentions for Niagen Bioscience and 1 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.68 beat Niagen Bioscience's score of 0.48 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation and earnings, NAGE or EPRX? Niagen Bioscience has higher revenue and earnings than Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNiagen Bioscience$99.60M7.79$8.55M$0.1757.24Eupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-6.92 Do institutionals and insiders believe in NAGE or EPRX? 15.4% of Niagen Bioscience shares are owned by institutional investors. 9.4% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryNiagen Bioscience beats Eupraxia Pharmaceuticals on 11 of the 15 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.64M$2.97B$5.44B$9.61BDividend YieldN/A2.46%4.61%4.14%P/E Ratio-6.9216.9029.7624.84Price / SalesN/A313.57449.1298.65Price / CashN/A41.8536.4258.36Price / BookN/A7.318.185.64Net Income-$25.50M-$54.43M$3.26B$265.68M7 Day Performance-0.83%0.00%6.88%4.95%1 Month Performance-3.66%1.33%1.00%0.83%1 Year Performance96.27%8.64%28.85%22.18% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.7427 of 5 stars$5.26-2.4%$11.00+109.1%+108.7%$193.64MN/A-6.9229NAGENiagen Bioscience1.3286 of 5 stars$9.65-0.1%$13.22+37.0%N/A$760.13M$99.60M56.76120News CoverageEarnings ReportAnalyst RevisionGHRSGH Research2.7389 of 5 stars$14.51-3.1%$32.00+120.5%+18.3%$754.96MN/A-18.3710Positive NewsEarnings ReportVIRVir Biotechnology2.8198 of 5 stars$5.39+2.6%$30.25+461.7%-50.1%$744.42M$74.21M-1.28580News CoverageEarnings ReportShort Interest ↑ANABAnaptysBio2.3623 of 5 stars$25.06-4.4%$47.13+88.1%-37.4%$732.74M$91.28M-5.14100News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAMLXAmylyx Pharmaceuticals2.8206 of 5 stars$8.12+2.2%$11.75+44.7%+324.4%$728.27M$87.37M-2.63200News CoverageEarnings ReportDAWNDay One Biopharmaceuticals2.809 of 5 stars$7.12+1.8%$29.00+307.6%-53.5%$720.67M$131.16M-10.0160Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSTOKStoke Therapeutics3.9506 of 5 stars$13.01+4.1%$25.80+98.3%-7.4%$712.04M$36.56M16.51100Upcoming EarningsKALVKalVista Pharmaceuticals3.7829 of 5 stars$14.24+3.6%$26.29+84.6%-4.9%$710.29MN/A-3.85100MNMDMind Medicine (MindMed)2.0551 of 5 stars$9.36+2.4%$24.00+156.5%+28.3%$707.75MN/A-7.2640Trending NewsAnalyst RevisionATAIatai Life Sciences2.9966 of 5 stars$3.50+5.6%$11.25+221.9%+215.3%$707.59M$1.86M-3.8880Upcoming EarningsShort Interest ↑ Related Companies and Tools Related Companies Niagen Bioscience Competitors GH Research Competitors Vir Biotechnology Competitors AnaptysBio Competitors Amylyx Pharmaceuticals Competitors Day One Biopharmaceuticals Competitors Stoke Therapeutics Competitors KalVista Pharmaceuticals Competitors Mind Medicine (MindMed) Competitors atai Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts